Prime Therapeutics to present latest managed care pharmacy insights at AMCP Nexus 2025

Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care

EAGAN, Minn., Oct. 27, 2025 /PRNewswire/ -- As health care costs continue to rise, Prime Therapeutics (Prime) is providing essential leadership and data-driven insights to drive affordability and access in health care. At the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference in National Harbor, Maryland on Oct. 27–30, Prime will present five research posters and lead educational sessions on key industry topics, including cost and clinical issues that matter to health care purchasers.

"Patients and providers face unprecedented uncertainty and rising costs across the health care ecosystem, so it's our responsibility as a trusted partner to deliver fact-based insights that promote improved affordability, access and health outcomes," said Steve Cutts, chief clinical and specialty officer at Prime.

Among the research posters presented at AMCP Nexus 2025:

• Three-Year Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Commercially Insured Adults with Obesity without Diabetes
  
  
• Trends in Real-World Persistence to Weight Loss Glucagon-Like Peptide-1 Receptor Agonists from 2021 to 2024 Among Commercially Insured Adults without Diabetes — This study earned a platinum award from AMCP.
  
  
• Impact of a Medical Claims Automated Glucagon Like Peptide-1 Drugs Prior Authorization Program — This study earned a gold award from AMCP.
  
  
• Validation of Long-term Savings from a Pharmacist-to-Prescriber Telephonic Intervention — This study earned a gold award from AMCP.
  
  
• Total Cost of Care and Adverse Effects Assessment of Bispecific T-cell Engagers and Chimeric Antigen Receptor T-cell Therapies for Relapsed Refractory Follicular Lymphoma

The GLP-1 persistence studies take an in-depth look at Prime's previously announced Year-3 real-world research of the popular obesity drugs.

"Prime's ongoing study of GLP-1s has positioned our organization as a leading voice on the impact of these drugs in the treatment of obesity but also the need to improve persistence and the subsequent health care costs associated with these therapies," Cutts said. "I'm proud to see all of our researchers awarded for their work at AMCP Nexus."

Visit the AMCP Nexus agenda for more details on the poster presentations and educational sessions. For more information on the studies, and for additional insights from the event, visit the Prime newsroom.

About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a pharmacy solutions partner that delivers savings, simplicity and support to customers and members. Prime provides care to millions of people across the country through pharmacy benefit management, specialty and medical drug management, and state government solutions. Prime creates a new standard for the industry by doing what's right through a conflict-free approach, offering a holistic specialty experience, accessing the most modern technology, and emphasizing purpose beyond profits. To learn more, visit PrimeTherapeutics.com or follow Prime on LinkedIn.

Contact: 
Alex Cook
Senior Public Relations Manager
612.777.4217
[email protected]  

SOURCE Prime Therapeutics